This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Vestibulotoxicity with gentamicin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Vestibulotoxicity with gentamicin

Gentamicin

  • is an aminoglycoside antibiotic composed of a mixture of related gentamicin components and fractions and is used for many types of bacterial infections treatment, particularly those caused by Gram-negative organisms
    • aminoglycosides are bactericidal antimicrobial agents that disrupt the integrity of the bacterial cell wall and impair bacterial protein synthesis
  • similar to all aminoglycosides, when gentamicin is given orally, it is not systemically active
    • is not absorbed to any appreciable extent from the small intestine
    • administered intravenously, intramuscularly, or topically to treat infections
    • eliminated, unchanged in the urine

Gentamicin is renally excreted within hours but accumulates over months in the inner ear

  • evident ototoxicity (hearing and/or vestibular loss) is estimated to affect 11% of people taking daily treatment with gentamicin, and between 0.2% and 6.2% of patients who have received a single dose (1)
  • vestibulotoxicity is considered to be dose dependent and commonly occurs when levels are high or renal clearance is poor
    • can occur in patients with preexisting renal damage and in patients with normal renal function treated at higher doses and/or for periods longer than those recommended (2)
    • other risk factors include increasing age, and concomitant use of other ototoxic drugs (3)
    • vestibulotoxic effect of gentamicin involves immediate inhibition of hair cell transmitter release by blocking mechanotransduction (3)
      • sustained exposure causes vestibular hair cell damage and death due to apoptosis
      • type I hair cells are more susceptible to loss than type II hair cells because they show an increased uptake and retention of gentamicin

Vestibulotoxicity with gentamicin:

  • most patients present with gait disturbance and imbalance (1)
    • possibly because systemic administration of gentamicin tends to affect bilateral vestibular function (1)
      • with acute bilateral vestibular loss will be unable to stand unaided
    • imbalance is worse while walking in the dark, and oscillopsia occurs during head movements (3)
      • vertigo is infrequent (3)
      • oscillopsia is a disabling condition in patients with bilateral vestibular hypofunction (BVH) (3)
        • when the vestibulo-ocular reflex (VOR) is bilaterally impaired, its ability to compensate for rapid head movements must be supported by refixation saccades
  • gentamicin is primarily toxic to the vestibular rather than auditory system (1)
    • majority (90%) of patients will not have accompanying hearing loss or tinnitus
    • vestibular loss is permanent in most patients

A review notes (1)

  • enquire about a history of gentamicin administration in patients who experience vestibular symptoms such as imbalance while walking or wobbly vision
  • gentamicin related vestibulotoxicity is often permanent, but prompt diagnosis and early physical rehabilitation can improve gait and balance
  • avoid gentamicin, if possible, for surgical prophylaxis and in patients with risk factors such as pre-existing kidney disease, overweight, or using other drugs that can potentiate its effects (such as vancomycin)

Reference:

  • Ferreira K, Forbes S, Kaski D. Vestibulotoxicity with gentamicin BMJ 2022; 378 :e070873
  • Saleh P, Abbasalizadeh S, Rezaeian S, Naghavi-Behzad M, Piri R, Pourfeizi HH. Gentamicin-mediated ototoxicity and nephrotoxicity: A clinical trial study. Niger Med J. 2016 Nov-Dec;57(6):347-352.
  • Ferreira-Cendon S, Martinez-Carranza R, Fernandez-Nava MJ, Villaoslada-Fuente R, Sanchez-Gomez H, Santa Cruz-Ruiz S, Sanchez-Ledesma M, Batuecas-Caletrio A. Prevention of Severe Vestibular Hypofunction after Systemic Gentamicin. J Clin Med. 2022 Jan 25;11(3):586.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.